Hello, Fool! | Login | Signup | My Fool
Jan 9, 2009 8:28 PM ET | Feedback | Site Changes | Help
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
View All Commentary (ENMD)
Recs
garupix (28.11) Submitted: 2/06/07 1:09 PM : Start Price: $1.65 ENMD Score: -47.68
Antiangiogenisis is a credible approach to treating cancerous tumors and ENMD pipeline drugs are performing well in Phase II clinical trials.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK